Pfizer PFE Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $14.45B+5.4% | $17.56B-1.2% | $16.65B-5.9% | $14.65B+10.3% | $13.72B-7.8% | ||
| $3.55B+24.7% | $5.27B-10.8% | $4.17B-20.7% | $3.78B+14.5% | $2.85B-15.8% | ||
| $10.9B+0.3% | $12.29B+3.6% | $12.48B+0.3% | $10.88B+8.9% | $10.87B-5.5% | ||
| 75.4%-3.8pp | 70%+3.2pp | 74.9%+4.7pp | 74.2%-0.9pp | 79.3%+2.0pp | ||
| $2.96B-2.3% | $4.16B-2.6% | $3.19B-1.8% | $3.42B-8.1% | $3.03B-13.3% | ||
| $1.61B+33.2% | $1.23B-9.5% | $1.22B-6.8% | $1.21B-7.3% | $1.21B-30.2% | ||
| $3.17B+13.8% | —— | $3.33B-29.3% | $3.04B+3,055% | $2.79B-18.6% | ||
| $461M+344% | -$2M+99.5% | -$216M-192% | $141M+205% | -$189M-165% | ||
| $2.69B-9.4% | —— | $3.54B-20.7% | $2.91B+6,998% | $2.97B-4.8% | ||
| 18.6%-3.0pp | —— | 21.3%-4.0pp | 19.9%+19.6pp | 21.6%+0.7pp | ||
| -$13M— | $0-100% | $0+100% | $25M+47.1% | $0+100% | ||
| $0.47-9.6% | —— | $0.62-20.5% | $0.51+5,000% | $0.52-5.5% | ||
| $0.47-9.6% | —— | $0.62-21.5% | $0.51+5,000% | $0.52-5.5% | ||
| 5.7B+0.4% | 5.7B+0.2% | 5.7B+0.2% | 5.7B+0.2% | 5.7B+0.2% | ||
| 5.7B+0.3% | 5.7B+0.3% | 5.7B+0.3% | 5.7B+0.3% | 5.7B+0.3% | ||
| $2.34B+10.7% | $2.58B+14.9% | $2.3B+20.9% | $2.27B+10.0% | $2.11B-2.7% | ||
| $1.18B-2.3% | $1.23B-9.5% | $1.22B-6.8% | $1.21B-7.3% | $1.21B-7.4% | ||
| $100M-85.3% | $605M-19.3% | $286M-8.6% | -$18M-101% | $678M+565% | ||
| $72M-52.6% | $1.02B+135% | $178M-63.4% | $3.34B+33.5% | $152M-17.4% | ||
| $0.48-7.7% | —— | $0.62-21.5% | $0.51+5,000% | $0.52-5.5% | ||
| $0.47-9.6% | —— | $0.62-21.5% | $0.51+5,000% | $0.52-5.5% | ||
| $0.00— | $0.00— | $0.00— | $0.00— | $0.00— | ||
| -$12M+98.2% | -$433M-9.3% | -$765M-58.7% | -$272M+65.3% | -$663M-50.3% | ||
| $72M-52.6% | $1.02B+135% | $178M-63.4% | $3.34B+33.5% | $152M-17.4% | ||
| $293M-17.0% | $981M-29.6% | $275M-1.8% | $1.13B-0.7% | $353M-14.9% | ||
| $62M-16.2% | $45M-69.4% | $66M+100% | —— | $74M+124% | ||
| -$2.86B+45.4% | $0+100% | -$2.48B+46.6% | -$3.2B-30.0% | -$5.23B-6.0% | ||
| $785M-76.0% | -$6.15B— | -$2.43B— | $3.95B-14.1% | $3.27B+89.0% | ||
| $2.62B+12.0% | $5.35B-20.4% | $4.6B-31.4% | $0+100% | $2.34B+114% | ||
| $93M+333% | $117M-93.5% | $292M-59.2% | $101M+125% | -$40M-126% | ||
| -$861M+9.7% | -$4.51B-91.4% | -$517M-113% | -$739M+33.2% | -$953M-40.1% | ||
| -$22M+92.7% | —— | -$14M-180% | —— | -$300M— | ||
| $792M-79.4% | —— | $583M— | —— | $3.85B+225% | ||
| $436M-22.7% | $845M-7.9% | $602M-7.5% | $618M-3.0% | $564M-19.9% | ||
| $2.57B-9.0% | $4.05B-34.5% | $4.22B+56.2% | $3.26B+614% | $2.82B+254% | ||
| -$284M+20.2% | -$43M-207% | -$38M-533% | -$21M+66.7% | -$356M+7.8% | ||
| -$127M+67.1% | —— | —— | -$517M— | -$386M+81.1% | ||
| $88M+7.3% | $591M+1,938% | $359M-70.8% | $63M+800% | $82M-73.1% | ||
| $0-100% | —— | —— | —— | $6.31B+80.8% | ||
| $0-100% | —— | —— | $151M-96.7% | $2.05B+524% | ||
| $2.49B+13.0% | $3.21B+5.6% | $2.55B-2.0% | $2.48B-7.9% | $2.2B-11.6% | ||
| $272M+60.0% | $225M+27.1% | $201M-26.6% | $203M-1.5% | $170M-22.7% | ||
| $2.45B+0.3% | $2.45B+2.7% | $2.44B+2.7% | $2.45B+2.7% | $2.44B+2.7% | ||
| $4.78B+8.6% | —— | $5B-22.8% | $4.67B+187% | $4.4B-26.0% | ||
| 33.1%+1.0pp | —— | 30%-6.6pp | 31.9%+19.6pp | 32.1%-7.9pp | ||
| $3.17B+13.8% | —— | $3.33B-29.3% | $3.04B+3,055% | $2.79B-33.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Pfizer's revenue?
- Pfizer (PFE) generated $63.3B in revenue over the trailing twelve months, up 1.4% year over year.
- Is Pfizer profitable?
- Pfizer reported $12.1B in net income over the trailing twelve months, a 15.7% net margin.
- What is Pfizer's earnings per share?
- Pfizer's diluted EPS over the trailing twelve months is $2.12.
- Where does Pfizer's income statement data come from?
- Every line is extracted from Pfizer's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
